RARE Corporate Alliance
The Global Genes RARE Corporate Alliance is a partnership of like-minded industry stakeholders committed to improving the lives of people with rare diseases.
Together, the Corporate Alliance collaborates with rare patient communities to meet vital needs, address inequities, and drive progress toward treatments and cures.
Join your peers in supporting Global Genes’ work and shared mission to eliminate the burdens of rare disease for patients and caregivers worldwide
Membership is open to pharmaceutical and biotech companies, industry and academia that want to support patient education, community building, and improved access to approved rare disease treatments.
Email us at CorporateEngagem[email protected] to learn more about becoming a RARE Corporate Alliance member.
RARE Corporate Alliance Prospectus
Join other leaders in driving progress in rare diseases.Download the Prospectus
Looking to Support Impactful Programs?
Learn more about how your organization can support Global Genes’ initiatives.Learn How to Support
RARE Corporate Alliance Partners Can
Share Your Resources
RARE Corporate Alliance Leadership Level partners can submit articles and resources to be shared with the thousands of people looking for information, connections, inspiration, and community.
Use the RARE Clinical Trials Hub
A new way for the rare community to easily learn about clinical trial opportunities. Our partners can take advantage of this new recruitment too.
Engage, Advance, & Learn
Expand your connections, get key learnings to guide your company’s activities, access patient communities, and increase awareness and visibility of your programs
Email us at [email protected]
to learn more about becoming a RARE Corporate Alliance member.
Current RARE Corporate Alliance Leadership Members
Current RARE Corporate Alliance Members
Corporate Alliance Directory
Want member-only access to the Corporate Alliance Directory?
Try our free one-on-one service for patients looking for information and resources on their rare disease.